An increase in sales of oncology, HIV and hepatitis C drugs boosted Gilead Sciences’ quarterly revenues by 2%, according to the company’s most recent earnings report released Thursday evening.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,